Navigation Links
Tailored Treatment Boosts Kidney Cancer Survival
Date:11/1/2008

Study concludes one-size-fits-all therapy needs to be changed

SATURDAY, Nov. 1 (HealthDay News) -- Personalized treatment of kidney cancer patients can increase survival, according to a UCLA study of almost 1,500 patients that identified subsets of kidney cancer that behave differently and need to be treated accordingly.

The UCLA team said their findings indicate the traditional one-size-fits-all treatment approach needs to be changed.

"We have shown that not all kidney cancer patients are the same, not all localized kidney cancers are the same, and not all metastatic kidney cancers are the same," study senior author Dr. Arie Belldegrun, a professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center, said in a UCLA news release.

Patients with localized kidney cancer can have either low-, intermediate-, or high-risk cancers based on the chance for recurrence, the researchers found. Patients with kidney cancer that's spread (metastatic cancer) can also be categorized into similar subsets.

"Now we can base treatment decisions based on that," Belldegrun said.

Patients with localized, low-risk kidney cancer have a projected five-year survival rate of 97 percent and a 10-year survival rate of 92 percent, compared to 81 percent and 61 percent for patients with localized, intermediate-risk cancer, and 62 percent and 41 percent for patients with localized, high-risk cancer.

"All these patients with cancers that have not spread present to their doctors with presumably localized disease, and in the past, they may have been treated the same way. They need to be treated individually, according to their risk levels," Belldegrun said.

For example, the UCLA team showed that surgery alone can produce excellent outcomes in patients with localized, low-risk, kidney cancer, meaning they could be spared the harsh side effects associated with radiation or immunotherapy. But surgery alone isn't sufficient for patients with localized, high-risk kidney cancer.

Patients with metastatic, low-risk cancer should get very aggressive treatment, because there's a good chance the therapy will benefit them. But patients with metastatic, high-risk cancer may choose to decline treatment, because they'll get little or no benefit from it.

"Our paper identifies, very precisely, which patients should get which therapies," Belldegrun said.

The study was published in the Nov. 1 issue of Cancer.

More information

The American Urological Association has more about kidney cancer.



-- Robert Preidt



SOURCE: University of California, Los Angeles, news release, Nov. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach
2. Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox
3. ENT doctors release national guideline on treatment for common cause of dizziness
4. Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival
5. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
6. Health Secretary Raises Awareness About Diabetes; Rising Costs of Treatment
7. If metastasectomy should be performed before other treatments
8. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
9. Combo Treatment Best for Anxiety Disorder in Kids
10. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
11. PURE Bioscience Granted US Patent on SDC for Food Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tailored Treatment Boosts Kidney Cancer Survival
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch ... world headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra ... personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness program ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
Breaking Medicine Technology: